Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a
century after they were first described. Two bispecific antibodies, catumaxomab (Removab® …

A steady increase of product titers and the corresponding change in impurity composition
represent a challenge for development and optimization of antibody production processes …

Monoclonal antibodies (mAbs) have established themselves as the leading
biopharmaceutical therapeutic modality. The establishment of robust manufacturing …

Building upon the resounding therapeutic success of monoclonal antibodies, and supported
by accelerating progress in engineering methods, the field of multispecific therapeutic …

Biologic products encounter various types of interfacial stress during development,
manufacturing, and clinical administration. When proteins come in contact with vapor–liquid …

Evanescent-wave optical biosensors have become an attractive alternative for the screening
of nucleic acids in the clinical context. They possess highly sensitive transducers able to …

Integrated and continuous processing of recombinant proteins offers several advantages
over batch or semi‐batch processing used traditionally in the biotechnology industry. This …

The use of biological systems to synthesize complex therapeutic products has been a
remarkable success. However, during product development, great attention must be devoted …

A twin-column counter-current chromatography processes, CaptureSMB, was used for the
protein A affinity capture of a monoclonal antibody (mAb). By means of sequential loading …

Monoclonal antibodies (mAbs) are the most important family of biopharmaceutical
compounds in terms of market share. At present, 30 mAbs have been approved and are now …